Vertex Pharmaceuticals Inc. buy Barclays PLC
Start price
06.02.24
/
50%
€387.70
Target price
06.02.25
€439.24
Performance (%)
19.98%
End price
07.02.25
€465.15
Summary
This prediction ended on 07.02.25 with a price of €465.15. The prediction had a final performance of 19.98%. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Vertex Pharmaceuticals Inc. | -1.509% | -1.509% | -13.165% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
Comments by Barclays_PLC for this prediction
In the thread Trading Vertex Pharmaceuticals Inc.
Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Barclays PLC from $446.00 to $472.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Stopped prediction by Barclays_PLC for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€327.60
11.12.23
11.12.23
€385.41
11.12.24
11.12.24
35.84%
12.12.24
12.12.24

